Cargando…

The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome

(1) The metabolic syndrome (MS) promotes acute and chronic infections, due to the pro-inflammatory condition given by TNFα and IL6 or by affecting the microbiota. MS is also correlated with insulin resistance, causing inflammation and infections throughout the organism. (2) The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghitea, Timea Claudia, El-Kharoubi, Amina, Ganea, Mariana, Bimbo-Szuhai, Erika, Nemeth, Tiberiu Sebastian, Ciavoi, Gabriela, Foghis, Monica, Dobjanschi, Luciana, Pallag, Annamaria, Micle, Otilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827761/
https://www.ncbi.nlm.nih.gov/pubmed/33429991
http://dx.doi.org/10.3390/molecules26020283
_version_ 1783640845913686016
author Ghitea, Timea Claudia
El-Kharoubi, Amina
Ganea, Mariana
Bimbo-Szuhai, Erika
Nemeth, Tiberiu Sebastian
Ciavoi, Gabriela
Foghis, Monica
Dobjanschi, Luciana
Pallag, Annamaria
Micle, Otilia
author_facet Ghitea, Timea Claudia
El-Kharoubi, Amina
Ganea, Mariana
Bimbo-Szuhai, Erika
Nemeth, Tiberiu Sebastian
Ciavoi, Gabriela
Foghis, Monica
Dobjanschi, Luciana
Pallag, Annamaria
Micle, Otilia
author_sort Ghitea, Timea Claudia
collection PubMed
description (1) The metabolic syndrome (MS) promotes acute and chronic infections, due to the pro-inflammatory condition given by TNFα and IL6 or by affecting the microbiota. MS is also correlated with insulin resistance, causing inflammation and infections throughout the organism. (2) The purpose of this study was to track the effect of using the essential oil of Origanum vulgare L. (EOO) as an antibacterial treatment, compared to allopathic treatment with antibiotics in MS patients. A group of 106 people with MS was divided into four subgroups: L1—staphylococcal infection group, L2—Escherichia coli infection group, L3—streptococcal infection group with EOO treatment, and CG—control group without infection or treatment. (3) EOO is responsible for the antibacterial effect, and reduced minor uncomplicated infections. After a 10-day treatment, intestinal side effects were absent, improving the phase angle. (4) The results suggest that EOO may exhibit an antibacterial effect, similar to the antibiotic treatment, without promoting MS-specific dysbiosis, and it also improves the phase angle in patients, which is used as an index of health and cellular function.
format Online
Article
Text
id pubmed-7827761
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78277612021-01-25 The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome Ghitea, Timea Claudia El-Kharoubi, Amina Ganea, Mariana Bimbo-Szuhai, Erika Nemeth, Tiberiu Sebastian Ciavoi, Gabriela Foghis, Monica Dobjanschi, Luciana Pallag, Annamaria Micle, Otilia Molecules Article (1) The metabolic syndrome (MS) promotes acute and chronic infections, due to the pro-inflammatory condition given by TNFα and IL6 or by affecting the microbiota. MS is also correlated with insulin resistance, causing inflammation and infections throughout the organism. (2) The purpose of this study was to track the effect of using the essential oil of Origanum vulgare L. (EOO) as an antibacterial treatment, compared to allopathic treatment with antibiotics in MS patients. A group of 106 people with MS was divided into four subgroups: L1—staphylococcal infection group, L2—Escherichia coli infection group, L3—streptococcal infection group with EOO treatment, and CG—control group without infection or treatment. (3) EOO is responsible for the antibacterial effect, and reduced minor uncomplicated infections. After a 10-day treatment, intestinal side effects were absent, improving the phase angle. (4) The results suggest that EOO may exhibit an antibacterial effect, similar to the antibiotic treatment, without promoting MS-specific dysbiosis, and it also improves the phase angle in patients, which is used as an index of health and cellular function. MDPI 2021-01-08 /pmc/articles/PMC7827761/ /pubmed/33429991 http://dx.doi.org/10.3390/molecules26020283 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ghitea, Timea Claudia
El-Kharoubi, Amina
Ganea, Mariana
Bimbo-Szuhai, Erika
Nemeth, Tiberiu Sebastian
Ciavoi, Gabriela
Foghis, Monica
Dobjanschi, Luciana
Pallag, Annamaria
Micle, Otilia
The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome
title The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome
title_full The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome
title_fullStr The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome
title_full_unstemmed The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome
title_short The Antimicrobial Activity of Origanum vulgare L. Correlated with the Gastrointestinal Perturbation in Patients with Metabolic Syndrome
title_sort antimicrobial activity of origanum vulgare l. correlated with the gastrointestinal perturbation in patients with metabolic syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827761/
https://www.ncbi.nlm.nih.gov/pubmed/33429991
http://dx.doi.org/10.3390/molecules26020283
work_keys_str_mv AT ghiteatimeaclaudia theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT elkharoubiamina theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT ganeamariana theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT bimboszuhaierika theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT nemethtiberiusebastian theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT ciavoigabriela theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT foghismonica theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT dobjanschiluciana theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT pallagannamaria theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT micleotilia theantimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT ghiteatimeaclaudia antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT elkharoubiamina antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT ganeamariana antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT bimboszuhaierika antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT nemethtiberiusebastian antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT ciavoigabriela antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT foghismonica antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT dobjanschiluciana antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT pallagannamaria antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome
AT micleotilia antimicrobialactivityoforiganumvulgarelcorrelatedwiththegastrointestinalperturbationinpatientswithmetabolicsyndrome